Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis

被引：0
|
作者：
Hansen, Karen E. [1 ]
Mortezavi, Mahta [2 ]
Nagy, Edward [3 ]
Wang, Cunshan [4 ]
Connell, Carol A. [4 ]
Radi, Zaher [5 ]
Litman, Heather J. [6 ]
Adami, Giovanni [7 ]
Rossini, Maurizio [7 ]
机构：
[1] Univ Wisconsin, Rheumatol Div, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Ltd, Tadworth, England
[4] Pfizer Inc, Groton, CT USA
[5] Pfizer Inc, Cambridge, MA USA
[6] CorEvitas LLC, Waltham, MA USA
[7] Univ Verona, Dept Med, Rheumatol Unit, Verona, Italy
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1431
引用
收藏
页码：2821 / 2824
页数：4
相关论文
共 50 条
  • [31] Tofacitinib versus Methotrexate in Rheumatoid Arthritis
    Sexton, Donal
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (12): : 1163 - 1163
  • [32] Tofacitinib versus Methotrexate in Rheumatoid Arthritis
    Lunzer, R.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2014, 21 (04): : 157 - 157
  • [33] FDA approves tofacitinib for rheumatoid arthritis
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (24) : 2120 - 2120
  • [34] Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
    Dougados, Maxime
    Charles-Schoeman, Christina
    Szekanecz, Zoltan
    Giles, Jon T.
    Ytterberg, Steven R.
    Bhatt, Deepak L.
    Koch, Gary G.
    Vranic, Ivana
    Wu, Joseph
    Wang, Cunshan
    Kwok, Kenneth
    Menon, Sujatha
    Connell, Carol A.
    Yndestad, Arne
    Rivas, Jose L.
    Buch, Maya H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 575 - 577
  • [35] IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Dougados, M.
    Charles-Schoeman, C.
    Szekanecz, Z.
    Giles, J. T.
    Ytterberg, S. R.
    Bhatt, D. L.
    Koch, G. G.
    Vranic, I.
    Wu, J.
    Wang, C.
    Kwok, K.
    Menon, S.
    Connell, C. A.
    Yndestad, A.
    Rivas, J. L.
    Buch, M. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 175 - 176
  • [36] Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
    Yun, Huifeng
    Xie, Fenglong
    Chen, Lang
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [37] Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis
    Navarro, Erika P.
    Posso-Osorio, Ivan
    Aguirre-Valencia, David
    Naranjo-Escobar, Juan
    Tobon, Gabriel J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 (02) : E58 - +
  • [38] The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
    Harter, Lauren
    Shin, Daniel
    Baker, Joshua F.
    Takeshita, Junko
    Love, Thorvardur
    Gelfand, Joel
    Ogdie, Alexis
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [39] Tofacitinib versus Methotrexate in Rheumatoid Arthritis REPLY
    Wilkinson, Bethanie
    Krishnaswami, Sriram
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (12): : 1164 - 1165
  • [40] TOFACITINIB IN RHEUMATOID ARTHRITIS: REAL LIFE EXPERIENCE
    Sansinanea, P.
    Costi, A. C.
    Vulcano, A.
    Salas, A. P.
    Marcos, J.
    Belini, M. A.
    Garcia, M. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1202 - 1202
12345